Deuruxolitinib
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Exploring novel management options for alopecia areata.
Journal: The American journal of managed care
Published: March 04, 2026
Efficacy, Safety, and Real-World Aspects of Janus Kinase Inhibitors to Treat Patients With Alopecia Areata.
Journal: Journal of drugs in dermatology : JDD
Published: March 04, 2026
Deuruxolitinib (Leqselvi) for severe alopecia areata.
Journal: The Medical letter on drugs and therapeutics
Published: October 21, 2025
Treatment of alopecia areata with JAK inhibitors: a review of the literature.
Journal: Acta dermatovenerologica Alpina, Pannonica, et Adriatica
Published: August 25, 2025
Comparative Efficacy of Janus Kinase Inhibitors Indicated for Severe Alopecia Areata: A Bayesian Network Meta-Analysis and Matching-Adjusted Indirect Comparison.
Journal: The Journal of dermatology
Published: August 04, 2025
Association of Janus kinase inhibitors with reduced depression in alopecia areata.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: July 25, 2025
Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.
Journal: Dermatology and therapy
Published: June 29, 2025
Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.
Journal: Frontiers in medicine
Published: June 04, 2025
Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial.
Journal: Journal of the American Academy of Dermatology
Published: April 10, 2025
Last Updated: 04/28/2026